Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

ABSTRACT Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5‐year longitudinal change of the MDS‐UPDRS and other clinical measures using results from the Parkinson's Progres...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2018-05, Vol.33 (5), p.771-782
Main Authors: Simuni, Tanya, Siderowf, Andrew, Lasch, Shirley, Coffey, Chris S., Caspell‐Garcia, Chelsea, Jennings, Danna, Tanner, Caroline M., Trojanowski, John Q., Shaw, Leslie M., Seibyl, John, Schuff, Norbert, Singleton, Andrew, Kieburtz, Karl, Toga, Arthur W., Mollenhauer, Brit, Galasko, Doug, Chahine, Lana M., Weintraub, Daniel, Foroud, Tatiana, Tosun, Duygu, Poston, Kathleen, Arnedo, Vanessa, Frasier, Mark, Sherer, Todd, Chowdhury, Sohini, Marek, Kenneth
Format: Article
Language:English
Subjects:
Age Factors
Aged
Amyloid beta-Peptides - metabolism
Cohort Studies
Corpus Striatum - diagnostic imaging
Corpus Striatum - drug effects
Disease Progression
disease subtypes
Dopamine
Dopamine Plasma Membrane Transport Proteins - metabolism
Dopamine receptors
Dopamine transporter
Female
gait disorder predominant
Humans
Male
Middle Aged
Movement disorders
Neostriatum
Neurodegenerative diseases
Nortropanes - pharmacokinetics
Parkinson Disease - diagnostic imaging
Parkinson Disease - metabolism
Parkinson's disease
Peptide Fragments - metabolism
postural instability
tau Proteins - metabolism
tremor dominant
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5‐year longitudinal change of the MDS‐UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123‐I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS‐UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P 
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.27361